What Katalyze AI does
Katalyze AI provides an agentic platform for pharmaceutical manufacturers that unifies data from MES, LIMS, ERP and more than 40 other plant systems, then lets operations teams build no-code AI agents (via its Agent Studio and Katalyst assistant) to handle batch monitoring, deviation investigations and quality control. The company says it is deployed at five of the world's twenty largest pharmaceutical companies, including Sanofi, and that it cuts batch-release time by about 40 percent and deviation-investigation time by half. Katalyze AI was co-founded by CEO Reza Farahani, a former Sanofi leader, and is backed by Inovia Capital and Ripple Ventures.
Katalyze AI is an automation tool on Falcoscan. No-code AI agents that automate pharmaceutical manufacturing operations. Falcoscan rates Katalyze AI with an Opportunity score of 74/100, a Saturation score of 23/100, and a Wrapper-risk score of 15/100. Market signal: hot. Katalyze AI is founded in 2023, currently at Seed stage. Pricing: Paid.